This product is an ASHP Learning Center activity.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

This self-paced, online professional certificate track is designed for pharmacists who are interested in expanding their knowledge and skills in oncology and hematology disease states for specialty pharmacy.

The Specialty Pharmacy Certificate is self-guided, with online learning activities that have been created for pharmacists and pharmacy technicians seeking to expand their skills in specialty pharmacy.

A learner will have completed the Specialty Pharmacy Fundamentals before beginning the Oncology and Hematology Disease States Track.

The learner will take a deep dive into their selected specialty focus area with the Oncology and Hematology Disease States Track. These topics include oncology supportive care, breast cancer, dem-oncology, neuro-oncology, colorectal cancer, hematology (AML, ALL, CML, CLL, multiple myeloma), stem cell transplant, hepatic and renal cancer, prostate cancer, and non-small cell lung cancer.

Once a learner has completed the Specialty Pharmacy Fundamentals and the Oncology and Hematology Disease States Track educational curriculum, they will have the opportunity to complete the track final exam. Once the learner successfully completes the track final exam (minimum 80% passing rate; unlimited attempts permitted), they will earn the professional certificate.

Introduction to Oncology Care
ACPE: 0204-0000-23-756-H04-P
2 contact hours

Learning Objectives:

• Differentiate hematology/oncology organizations and their roles in practice.
• Define basic hematology/oncology concepts, including terminology, tumor staging, and dosing.
• Apply guideline recommendations in choosing an antiemetic regimen for cancer patients.
• Select agents for management of acute and chronic graft-versus-host disease (GVHD).
• Analyze patient characteristics for appropriate use of granulocyte colony stimulating factor (GCSF).

Breast Cancer
ACPE: 0204-0000-23-757-H01-P
2.25 contact hours

Learning Objectives:

• Summarize breast cancer risk factors, epidemiology, pathophysiology, diagnosis, and tumor markers.
• Develop a patient-specific pharmacotherapy plan for early-stage breast cancer.
• Explain recurrent and metastatic breast cancer characteristics and pathology.
• Compare therapies used in HR+ recurrent and metastatic breast cancer.
• Compare targeted medication therapies for recurrent and metastatic breast cancer.
• Develop a patient-specific medication therapy treatment plan for a patient with breast cancer.

Derm-oncology, Neuro-oncology, and Colorectal Cancer
ACPE: 0204-0000-23-758-H01-P
2.25 contact hours

Learning Objectives:

• Summarize cutaneous oncology risk factors, epidemiology, pathophysiology, diagnosis, and tumor markers.
• Develop a patient-specific pharmacotherapy plan for basal cell carcinoma.
• Develop a patient-specific pharmacotherapy plan for melanoma.
• Develop a patient-specific pharmacotherapy plan for primary cutaneous t-cell lymphoma.
• Explain neuro-oncology risk factors, epidemiology, pathophysiology, diagnosis, and tumor markers.
• Construct a patient-specific pharmacotherapy plan for neuro-oncology.
• Summarize gastrointestinal (GI) cancer risk factors, epidemiology, pathophysiology, diagnosis, and tumor markers.
• Develop a patient-specific pharmacotherapy plan for gastrointestinal cancers.
• Develop a patient-specific pharmacotherapy plan for gastrointestinal stromal tumors.

Hematology and Stem Cell Transplant
ACPE: 0204-0000-23-759-H01-P
4.25 contact hours

Learning Objectives:

• Given a patient case, choose an appropriate acute myeloid leukemia (AML) treatment regimen based on next-generation sequencing (NGS).
• Given a patient case, choose an appropriate acute lymphocytic leukemia (ALL) treatment regimen.
• Given a patient case, choose an appropriate chronic myeloid leukemia (CML) treatment regimen.
• Evaluate tyrosine kinase inhibitors (TKIs) based on patient characteristics and response.
• Given a patient case, choose an appropriate chronic lymphocytic leukemia (CLL) treatment regimen.
• Analyze patient risk factors in starting Bruton's tyrosine kinase (BTK) inhibitors.
• Adjust multiple myeloma (MM) regimens based on patient lab values.
• Modify therapy in the management of a stem cell transplant recipient.

Hepatic and Renal Cancer
ACPE: 0204-0000-23-760-H01-P
1.5 contact hours

Learning Objectives:

• Calculate a Child-Pugh Score.
• Choose a treatment regimen for a patient with hepatocellular carcinoma (HCC).
• Apply guideline recommendations when changing treatment of a patient with metastatic renal cell carcinoma (mRCC).
• Differentiate between immune-mediated vs. targeted therapy side effects.

Prostate Cancer
ACPE: 0204-0000-23-761-H01-P
1.25 contact hours

Learning Objectives:

• Summarize prostate cancer risk factors, epidemiology, pathophysiology, diagnosis, and tumor markers.
• Develop a patient-specific pharmacotherapy plan for localized prostate cancer.
• Develop a patient-specific pharmacotherapy plan for metastatic prostate cancer.

Thoracic Cancer
ACPE: 0204-0000-23-762-H01-P
1.5 contact hours

Learning Objectives:

• Summarize non-small cell lung cancer (NSCLC) risk factors, epidemiology, pathophysiology, diagnosis, and tumor markers.
• Develop a patient-specific NSCLC pharmacotherapy plan for an EGFR or KRAS-type mutation.
• Develop a patient-specific NSCLC pharmacotherapy plan for an ALK, ROS1, or BRAF-type mutation.
• Develop a patient-specific NSCLC pharmacotherapy plan for an MET, NTRK, or RET-type mutation.

Jared Crumb, PharmD
Clinical Pharmacist
Vanderbilt University Medical Center
Nashville, Tennessee

Sarah Kjenstad, PharmD, BCPS, BCOP
Clinical Pharmacist, Hematology/Oncology
Northwestern Medicine
Chicago, Illinois
Adjunct Assistant Professor
Midwestern University College of Pharmacy
Downers Grove, Illinois

In accordance with our accreditor's Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

• No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

This online activity consists of a combined total of 7 learning modules. Pharmacists are eligible to receive a total of 15 hours of continuing education credit by completing all 7 modules within this professional certificate track.

Participants must participate in the entire activity and complete the evaluation and all required components to claim continuing pharmacy education credit online at ASHP Learning Center. Follow the prompts to claim credit and view your statement of credit within 60 days of completing the activity.

Important Note – ACPE 60 Day Deadline:
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, check your NABP eProfile account to validate that your credits were transferred successfully before the ACPE 60-day deadline. After the 60-day deadline, ASHP will no longer be able to award credit for this activity.

System requirements courses and learning activities are delivered via your web browser and Acrobat PDF. Users should have a basic comfort level using a computer and navigating web sites. View the minimum technical and system requirements for learning activities.